Scientia Crosp. z o.o.

Other research and experimental development on natural sciences and engineering

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2022-10-27
Share capital
5,000.00 PLN
Activity description

Scientia Cro is a contract research organization (CRO) that conducts and oversees commercial and non-commercial clinical studies across Poland, working with partners in Europe and the USA. It runs projects involving pharmaceutical products and medical devices from early to advanced stages, including in oncology, cardiology and rare diseases.

Registered address
ul. Michała Kleofasa Ogińskiego 2, 85-092 Bydgoszcz, Poland
Website
scientiacro.com
Email
Phone
Electronic delivery address
AE:PL-52098-88540-FRTIV-14

Financials

Total Operating Costs
525.47k
+31.8% vs 2023

Revenue history (in k)

Filing timeliness

2 of 4 financial statements were filed late (the longest delay 38 days for 2025).

  • 202522/08/2026
  • 202410/04/2025
  • 202301/07/2024
  • 202220/07/2023
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue
This companyUSD 607.62kMedianUSD 73.59kAverageUSD 3.23m
Net profit
This companyUSD 76.69kMedianUSD 68.18AverageUSD 82.15k
Operating costs
This companyUSD 525.47kMedianUSD 76.09kAverageUSD 3.04m
Assets
This companyUSD 600.60kMedianUSD 120.07kAverageUSD 3.90m

Industry

Offer

  • Clinical trials
  • Observational studies
  • Clinical trial management
  • Medical data analysis
  • Research consulting
  • Clinical research training

Website technology

Website
  • WordPress

Public procurement

5 tenders recorded as contractor: 1 national ($26,051) and 4 EU ($666,936).

SubjectAmount
Provision of Clinical Research Organisation (CRO) services under the project: “Comparison of ustekinumab, infliximab and COMBinatiOn therapy in moderately-to-severely active Ulcerative Colitis – the head to head combo-uc trial”
$209.8K
Service for supervising the comprehensive implementation of the medical experiment “Ocena bezpieczeństwa i skuteczności zabiegu wewnątrznaczyniowego techniką cerab u pacjentów z zaawansowanymi zmianami miażdżycowymi odcinka aortalno-biodrowego w porównaniu do chirurgicznego zabiegu implantacji protezy aortalno-dwuudowej – badanie randomizowane”.
$149.6K
Supervision of the comprehensive conduct of the clinical trial (CRO) in the United Kingdom
$307.6K

Authorized Representatives

Beata Maciejewska – President of the Management Board
Przemysław Magielski – Management Board Member

Manner of representation

Each member of the management board is entitled to make declarations on behalf of the company independently.

Ownership

OwnerSharesShare valueStake
Beata Maciejewskaage 54
80$1,080.5080%
Hubert Maciejewskiage 22
20$270.1220%

Beata Maciejewska and Hubert Maciejewski hold a combined 100% – the ownership structure indicates family control.

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2022-11-24.

  • mBank
    mBank
    36 1140 2004 0000 3002 8306 9383

Debt

No entries in the National Debtors Register (KRZ).

Public aid

PurposeGross amount
De minimis aid (in accordance with Commission Regulation 2023/2831)
–
De minimis aid (in accordance with Commission Regulation 2023/2831)
–
De minimis aid (in accordance with Commission Regulation 2023/2831)
–

Competitors

Name
Pure Clinicalsp. z o.o.
Medsource Polskasp. z o.o.
Saventic Healthsp. z o.o.
DR Koziejsp. z o.o. + limited partnership
Medrisesp. z o.o.
CTI Clinical Trial and Consulting Services Polandsp. z o.o.
Centrum Innowacji Uniwersytetu Rolniczego w Krakowiesp. z o.o.
SKIN Lab Internationalsp. z o.o.
CCTSsp. z o.o.
TCIsp. z o.o.

Change history

DateEvent
2022-12-12Name change
2022-10-27Entered in the register

FAQ

Last updated: 2026-08-22